Jacqueline Morby died peacefully on May 12, 2026, with her beloved children Michelle and Drew by her side. Known by all as Jacqui, she led an extraordinary life defined by her sharp intelligence, spirit of adventure, generous nature, and the constant twinkle in her eye. She approached every challenge with matter-of-fact determination and was never as impressed by her myriad accomplishments as were all those around her. Jacqui had a gift for both immediate and deep connection. In her professional life, that gift translated into famous deal sourcing as a pioneer venture capitalist. In her personal life, the mutual devotion between Jacqui and Jeffrey L. Morby (1937 – 2023), her husband of 64 years, inspired everyone who knew them, and they were together dedicated to their children and their wide circle of friends. Individually, Jacqui and Jeff were remarkable; together, they were unstoppable, and they brought their same passion for exploring the world to making a positive impact on it through their many philanthropic efforts including co-founding Cure Alzheimer’s Fund.
To read more about Jacqui’s life and legacy please click here.
In lieu of flowers, and in recognition of Jacqui’s deep commitment to catalyzing research through sustaining Cure Alzheimer’s Fund, the family invites contributions in her memory to the Jacqui Morby Impact Fund at Cure Alzheimer’s Fund. This Fund recognizes Jacqui’s extraordinary leadership, vision, and commitment to accelerating research to prevent, slow, and reverse Alzheimer’s disease. It honors her legacy of service while helping sustain the mission she helped build. The Fund supports CureAlz’s operating expenses and organizational infrastructure reflecting the longstanding commitment of CureAlz’s founding Board members, to ensure that operational costs are fully supported so that other donor contributions can directly advance Alzheimer’s research. The Fund provides long-term and reliable support for CureAlz’s work for as long as the organization continues pursuing its mission to fund research with the highest probability of preventing, slowing, or reversing Alzheimer’s disease.